A dverse drug events are unfavourable occurrences related to the use and misuse of medications.
These staggering data suggest that we have underestimated the magnitude of this problem but also that we are presented with a tremendous opportunity to explore and implement strategies for both inpatients and outpatients to reduce these events. In this issue of the CJHP, we have 3 papers that once again remind us of the impact of adverse drug events and drug-related problems in hospital patients. [8] [9] [10] For over 20 years, pharmaceutical care has been the framework for our inpatient practice models. 11 Prolonged and continuous access to the patient, to the patient's information, and to other health care providers places hospital pharmacists in a unique practice setting ideal for the identification, resolution, and prevention of drug-related problems. However, despite attempts to improve the communication of patient information at the time of discharge to the community setting, it is well established that this transition is not seamless. Shortcomings in communication, follow-up, and monitoring place patients at risk in the immediate postdischarge period. 11, 12 In the longer term, the system of dispersed health care providers in the community setting creates ongoing access and communication challenges. The community pharmacist's access to the patient's information and to other health care providers is also limited. Together, the complexities of these issues contribute to the high rates of adverse drug events that are seen both shortly after hospital discharge 8 and in the longer-term, ambulatory care setting. 13 Examples exist of programs and practice models that attempt to address these problems. However, there remains an opportunity for hospital pharmacists, working with other health care providers, to further enhance the care provided to patients after discharge from hospital. There is also an opportunity for hospital pharmacists and community pharmacists to start collaborating more closely to provide truly patient-centred pharmaceutical care. Although having less influence on care provided in the hospital setting, the changes in pharmacy legislation that are occurring throughout the country have enabled community pharmacists to expand their scope of practice and to provide more comprehensive pharmacy services. In addition, appropriate remuneration models are being developed in some provinces to support expanded pharmacy practice activities. Finally, enhanced use of technology will start to improve information access in all practice settings, facilitating better collaboration between heath care providers in both inpatient and outpatient care settings.
We must start to think outside our box of hospital practice, to explore innovative practice models, and to embrace approaches that expand the provision of our expertise to patients and other health care providers after the patient's discharge from hospital. The solutions are not simple, but the magnitude of the impact of adverse drug events on our patients deserves our attention. Closer collaboration with the community-based health care providers who care for our patients after they leave the hospital is a good place to begin. I am confident that with careful attention, reflection, and willingness to provide patientcentred care, an improved model of collaboration with community-based health care providers will have a significant effect in reducing adverse drug events.
